Faculty Opinions recommendation of Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725609985.793524442 ◽

2016 ◽

Author(s):

Dafna Gladman

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A ◽

Download Full-text

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(15)61134-5 ◽

2015 ◽

Vol 386 (9999) ◽

pp. 1137-1146 ◽

Author(s):

Iain B McInnes ◽

Philip J Mease ◽

Bruce Kirkham ◽

Arthur Kavanaugh ◽

Christopher T Ritchlin ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A ◽

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718257967.793494565 ◽

2014 ◽

Author(s):

Christian Jorgensen ◽

Yves-Marie Pers

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2178 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 345.3-346 ◽

Author(s):

A. Kavanaugh ◽

I.B. McInnes ◽

S. Hall ◽

H. Chinoy ◽

A. Kivitz ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

THU0421 Secukinumab is Effective in Reducing Dactylitis and Enthesitis Using Multiple Measures in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2276 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 351.1-351 ◽

Author(s):

B. Kirkham ◽

I.B. McInnes ◽

P. Mease ◽

J. Kremer ◽

S. Kandala ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multiple Measures ◽

Download Full-text

Long‐term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through 2 Years: Results from a Phase 3, Randomized, Double‐blind, Placebo‐controlled Study Conducted in Biologic‐naïve Patients with Active Psoriatic Arthritis

Arthritis & Rheumatology ◽

10.1002/art.42010 ◽

2021 ◽

Author(s):

Iain B. McInnes ◽

Proton Rahman ◽

Alice B. Gottlieb ◽

Elizabeth C. Hsia ◽

Alexa P. Kollmeier ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Term Efficacy ◽

Download Full-text

073. SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY

Rheumatology ◽

10.1093/rheumatology/kex062.073 ◽

2017 ◽

Vol 56 (suppl_2) ◽

Author(s):

Bruce Kirkham ◽

Philip J. Mease ◽

Iain B. McInnes

Keyword(s):

Psoriatic Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Faculty Opinions recommendation of Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718283036.793491904 ◽

2014 ◽

Author(s):

Dafna Gladman ◽

Vinod Chandran

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Integrated Analysis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Radiographic Data

Download Full-text

THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2015-eular.2265 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 352.3-353 ◽

Author(s):

I.B. McInnes ◽

P. Mease ◽

B. Kirkham ◽

A. Kavanaugh ◽

C. Ritchlin ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Signs And Symptoms ◽

Controlled Study ◽

Dosing Regimen ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-204655 ◽

2014 ◽

Vol 73 (6) ◽

pp. 990-999 ◽

Author(s):

Christopher Ritchlin ◽

Proton Rahman ◽

Arthur Kavanaugh ◽

Iain B McInnes ◽

Lluis Puig ◽

...

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text